Suppr超能文献

3特斯拉下帕金森病的化学交换饱和转移磁共振成像

Chemical exchange saturation transfer MR imaging of Parkinson's disease at 3 Tesla.

作者信息

Li Chunmei, Peng Shuai, Wang Rui, Chen Haibo, Su Wen, Zhao Xuna, Zhou Jinyuan, Chen Min

机构信息

Department of Radiology, Beijing Hospital, No. 1 Da-Hua Road, Dong Dan, Beijing, 100730, China.

出版信息

Eur Radiol. 2014 Oct;24(10):2631-9. doi: 10.1007/s00330-014-3241-7. Epub 2014 Jul 20.

Abstract

OBJECTIVES

To demonstrate the feasibility of using chemical exchange saturation transfer (CEST) imaging to detect Parkinson's disease (PD) in patients at 3 Tesla.

METHODS

Twenty-seven PD patients (17 men and 10 women; age range, 54-77 years) and 22 age-matched normal controls (13 men and 9 women; age range, 55-73 years) were examined on a 3-Tesla MRI system. Magnetization transfer spectra with 31 different frequency offsets (-6 to 6 ppm) were acquired at two transverse slices of the head, including the basal ganglia and midbrain. One-way analysis of variance tests was used to compare the differences in CEST imaging signals between PD patients and normal controls.

RESULTS

Total CEST signal between the offsets of 0 and 4 ppm in the substantia nigra was significantly lower in PD patients than in normal controls (P = 0.006), which could be associated with the loss of dopaminergic neurons. Protein-based CEST imaging signals at the offset of 3.5 ppm in the globus pallidus, putamen and caudate were significantly increased in PD patients, compared to normal controls (P < 0.001, P = 0.003, P < 0.001, respectively).

CONCLUSIONS

CEST imaging signals could potentially serve as imaging biomarkers to aid in the non-invasive molecular diagnosis of PD.

KEY POINTS

• Total CEST signal in substantia nigra decreased in PD patients • Protein-based CEST signals in basal ganglia increased in PD patients • CEST could assist with the non-invasive molecular diagnosis for PD patients.

摘要

目的

证明在3特斯拉场强下使用化学交换饱和转移(CEST)成像检测帕金森病(PD)患者的可行性。

方法

对27例PD患者(17例男性和10例女性;年龄范围54 - 77岁)和22例年龄匹配的正常对照者(13例男性和9例女性;年龄范围55 - 73岁)在3特斯拉磁共振成像系统上进行检查。在头部的两个横断层面(包括基底节和中脑)采集具有31种不同频率偏移(-6至6 ppm)的磁化转移谱。采用单因素方差分析检验比较PD患者和正常对照者之间CEST成像信号的差异。

结果

PD患者黑质中0至4 ppm偏移范围内的总CEST信号显著低于正常对照者(P = 0.006),这可能与多巴胺能神经元的丧失有关。与正常对照者相比,PD患者苍白球、壳核和尾状核中3.5 ppm偏移处基于蛋白质的CEST成像信号显著增加(分别为P < 0.001、P = 0.003、P < 0.001)。

结论

CEST成像信号有可能作为成像生物标志物,辅助PD的非侵入性分子诊断。

关键点

• PD患者黑质中的总CEST信号降低 • PD患者基底节中基于蛋白质的CEST信号增加 • CEST可辅助PD患者的非侵入性分子诊断

相似文献

1
Chemical exchange saturation transfer MR imaging of Parkinson's disease at 3 Tesla.
Eur Radiol. 2014 Oct;24(10):2631-9. doi: 10.1007/s00330-014-3241-7. Epub 2014 Jul 20.
4
Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
Mov Disord. 2002 Sep;17(5):917-27. doi: 10.1002/mds.10214.
5
Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
Neurosurgery. 2006 Feb;58(2):256-62; discussion 256-62. doi: 10.1227/01.NEU.0000194845.19462.7B.
6
Case control study of diffusion tensor imaging in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1383-6. doi: 10.1136/jnnp.2007.121525. Epub 2007 Jul 5.
8
Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
PLoS One. 2012;7(4):e35397. doi: 10.1371/journal.pone.0035397. Epub 2012 Apr 17.
10
Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
Brain. 2000 Dec;123 Pt 12:2423-31. doi: 10.1093/brain/123.12.2423.

引用本文的文献

1
Amide proton transfer imaging of Alzheimer's disease and Parkinson's disease.
Magn Reson Lett. 2022 Oct 28;3(1):22-30. doi: 10.1016/j.mrl.2022.10.002. eCollection 2023 Feb.
2
Amide proton transfer-weighted magnetic resonance imaging for the evaluation of testicular spermatogenic function: a preliminary study.
Diagn Interv Radiol. 2025 Jul 8;31(4):392-398. doi: 10.4274/dir.2025.253248. Epub 2025 May 20.
3
Chemical exchange saturation transfer MRI for neurodegenerative diseases: An update on clinical and preclinical studies.
Neural Regen Res. 2026 Feb 1;21(2):553-568. doi: 10.4103/NRR.NRR-D-24-01246. Epub 2025 Jan 29.
4
PET, SPECT, and MRI imaging for evaluation of Parkinson's disease.
Am J Nucl Med Mol Imaging. 2024 Dec 15;14(6):371-390. doi: 10.62347/AICM8774. eCollection 2024.
5
Radiomic feature reliability of amide proton transfer-weighted MR images acquired with compressed sensing at 3T.
Int J Imaging Syst Technol. 2024 Mar;34(2). doi: 10.1002/ima.23027. Epub 2024 Jan 30.
7
Machine learning-based amide proton transfer imaging using partially synthetic training data.
Magn Reson Med. 2024 May;91(5):1908-1922. doi: 10.1002/mrm.29970. Epub 2023 Dec 14.
9
Evaluation of the molecular origin of amide proton transfer-weighted imaging.
Magn Reson Med. 2024 Feb;91(2):716-734. doi: 10.1002/mrm.29878. Epub 2023 Sep 25.
10
Biogenic Imaging Contrast Agents.
Adv Sci (Weinh). 2023 Sep;10(25):e2207090. doi: 10.1002/advs.202207090. Epub 2023 Jul 3.

本文引用的文献

1
In vivo imaging of glucose uptake and metabolism in tumors.
Nat Med. 2013 Aug;19(8):1067-72. doi: 10.1038/nm.3252. Epub 2013 Jul 7.
3
Imaging of glutamate in the spinal cord using GluCEST.
Neuroimage. 2013 Aug 15;77:262-7. doi: 10.1016/j.neuroimage.2013.03.072. Epub 2013 Apr 9.
4
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement.
J Magn Reson Imaging. 2013 Nov;38(5):1119-28. doi: 10.1002/jmri.24067. Epub 2013 Feb 25.
5
CEST: from basic principles to applications, challenges and opportunities.
J Magn Reson. 2013 Apr;229:155-72. doi: 10.1016/j.jmr.2012.11.024. Epub 2012 Dec 6.
6
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer.
Magn Reson Med. 2012 Dec;68(6):1764-73. doi: 10.1002/mrm.24520. Epub 2012 Oct 16.
7
Molecular pathology in neurodegenerative diseases.
Curr Drug Targets. 2012 Nov;13(12):1548-59. doi: 10.2174/138945012803530134.
10
Magnetic resonance imaging of glutamate.
Nat Med. 2012 Jan 22;18(2):302-6. doi: 10.1038/nm.2615.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验